Atlas Trials

Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS)

Clinical trial NCT00225992 · TERMINATED

Trial details

NCT number
NCT00225992
Sponsor
Oncology Specialties, Alabama
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Myelodysplastic Syndrome (MDS)
Start date
2004-02-01
Primary completion
2007-11-01

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.